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Abstract
Background: As our understanding of the etiology and mechanisms of cancer becomes more sophisticated and the number otf therapeutic options increases, phase
I oncology trials today have multiple primary objectives. Many such designs are now
‘seamless’, meaning that the trial estimates both the maximum tolerated dose and the
efficacy at this dose level. Sponsors often proceed with further study only with this
additional efficacy evidence. However, with this increasing complexity in trial design,
it becomes challenging to articulate fundamental operating characteristics of these
trials, such as (i) what is the probability that the design will identify an acceptable,
i.e. safe and efficacious, dose level? or (ii) how many patients will be assigned to an
acceptable dose level on average? Methods: In this manuscript, we propose a new
modular framework for designing and evaluating seamless oncology trials. Each module is comprised of either a dose assignment step or a dose-response evaluation, and
multiple such modules can be implemented sequentially. We develop modules from
existing phase I/II designs as well as a novel module for evaluating dose-response
using a Bayesian isotonic regression scheme. Results: We also demonstrate a freely
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available R package called seamlesssim to numerically estimate, by means of simulation, the operating characteristics of these modular trials. Conclusions: Together,
this design framework and its accompanying simulator allow the clinical trialist to compare multiple different candidate designs, more rigorously assess performance, better
justify sample sizes, and ultimately select a higher quality design.
keywords: phase I; phase II; dose escalation; recommended phase II dose
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Background

Current phase I oncology trial designs are often ‘seamless’ in nature [1], meaning both a
maximum tolerated dose (MTD) and an initial efficacy estimate at this dose level are
sought. Trial sponsors may be unwilling to proceed with further study without this
additional efficacy evidence [2]. We recently designed such a trial for relapsed/refractory
indolent lymphoma. The objective was to estimate the MTD and obtain preliminary
estimates of efficacy as measured by complete response. Success for this trial reflects
the seamless perspective: the primary objective is to identify a dose level that is both
tolerable and efficacious. As in all such trials, a key statistical concern is the potential for
uncertainty to compound across objectives. Future success in the pipeline depends
upon the current trial correctly estimating both the MTD and the response rate at this
estimated MTD.
Our understanding of both the etiology and mechanisms of many cancers has
increased over the past decades, and the number of therapeutic options has
correspondingly increased. However, one characteristic remaining relatively static is that
most trial designs are still variants of the ‘3+3’ algorithm [3, 4]. This is notable given that
the canonical reference for this design recommends against its use [5]. The continued
use of the 3+3 instead of demonstrably superior alternatives such as the continual
reassessment method [CRM, 6] highlights a persistent gap between method and
practice in this area, which is widened by the multifaceted objectives of seamless
oncology trials.
We argue that this gap can be bridged with an accessible framework for seamless
trial design and the software for simulating such designs. To that end, this paper has two
primary contributions. First, we develop a modular perspective for seamless oncology
trial design, which decomposes complex designs with multiple decision points into
simpler components. This atomic approach individualizes the choices required for
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seamless designs, thus providing a framework to evaluate the effect of each choice on
overall performance. Second, we present a seamless trial design simulator to conduct
this performance assessment, implemented in the R statistical environment [7–10] as a
freely available package called seamlesssim [11]. Users can evaluate the impact of each
design choice with respect to important operating characteristics.
Many model-based designs for recommending dose levels based upon safety and
efficacy have been proposed, including the bivariate CRM [bCRM, 12], ‘EffTox’ [13], the
trivariate CRM [TriCRM, 14], and others [15–26]. Some of these designs have even been
implemented in trial practice, like the use of an EffTox design to assess the performance
of sitravatinib and nivolumab in renal cell cancer [27] or a trial of FLAG-IDA and ponatinib
in myeloid leukemia [28], or the use of the bivariate CRM in a trial on T cell
co-stimulators for solid tumors [29]. However, these examples aside, the uptake of these
advanced designs has been slow, and protocols often try to satisfy these dual objectives
under the 3+3 framework. For example, a trial may estimate an MTD using the 3+3 and
then, under the assumption that it has been correctly identified, enroll an additional
‘expansion cohort(s)’ of subjects at a fixed dose level(s) and/or in different
subpopulations in order to evaluate efficacy [30–33]. An extreme example of this is the
KEYNOTE-001 trial of pembrolizumab, which started as a 3+3 trial of 10 subjects across
three dose levels and subsequently evolved into a multi-amendment trial enrolling a total
of 1235 subjects across multiple expansion cohorts [34, 35]. As of 2016, there were at
least four other phase I trials enrolling more than 1000 patients [36].
The favorable outcome of KEYNOTE-001 was unusual: a recent study found that
only 3.4% of phase I oncology trials that opened between Jan 1, 2000 and Oct 31, 2015
led to eventual approval [37], which is consistent with reported success rates from an
earlier study [38]. Stopping dose-escalation after a small number of subjects, as in the
3+3, risks ending at too low of a dose [31]; the subsequent expansion may stop for lack
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of efficacy, when a higher dose level might have been found to be efficacious. Or
escalation might have occurred too quickly, and lower dose levels, in addition to being
safer, are equally efficacious, which would only be revealed through a more methodical
exploration of efficacy across the full range of dose levels. This piecemeal approach to
seamless trial design makes difficult a formal assessment of operating characteristics
and highlights the challenges of quantifying the implications of multiple sequential
decision trials.
Recognizing these weaknesses, the FDA published draft guidance on designing
seamless oncology trials [1, 39]. However, because the FDA does not make design
recommendations, this guidance does not resolve the tension between logistical
simplicity on the one hand and a rigorous quantification of uncertainty on the other. To
that end, this paper outlines a modular framework that captures the decision points
made in designing a seamless oncology trial and gives several possible options for each
decision. Section 2 describes each module and presents our specific design choices
intended to adhere to the FDA guidance. We present a freely available trial simulator,
implemented in an R package called seamlesssim and an accompanying vignette, both
available via GitHub [11], allowing the user to evaluate and compare many design
options at once. Section 3 demonstrates this simulator with a numerical study. We show
that sensible choices for each module exist, and we provide the computational tools for
clinical trialists and statisticians to make this assessment.
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Figure 1: A high-level schematic of our two-stage, four-module framework for Phase
I/II seamless designs. Note that toxicity and efficacy are assessed concurrently in both
stages, rather than a stark divide between the two objectives, with toxicity the priority in
Stage 1, while efficacy is the focus of Stage 2. Trials may choose to stop after Stage 1 if
the Module 2 interim efficacy analysis is not promising.

2
2.1

Methods
Conceptual Framework

Our framework encompasses many styles of early phase, seamless-type trials. We allow
for two stages, both enrolling cohorts of subjects to an assigned dose level(s) and
following for toxicity or response endpoints; the second stage may be dropped if a
certain response threshold is not achieved in the first stage. Each stage is subdivided
into two ‘modules’, one for dosing subjects and one for assessing efficacy, for up to four
modules total. Figure 1 provides a high-level schematic of our framework.
This paper defines a ‘seamless design’ to be any valid combination of the four
modules. Since each module can be selected independently of the remaining modules,
with some exceptions, there are many possible designs. Some modules can be skipped
altogether, and thus our schema includes both classical phase I dose-escalation
designs, such as the 3+3 or the CRM, and two-stage phase II designs [40]. It also yields
novel hybridizations of the two, and we elucidate the benefits and pitfalls of these
6

hybridizations. The specific choices for each module that we have considered are
summarized in Table 1. Throughout this document, we use a typewriter font family
to refer to the simulator and its inputs.
Remark 1 Our “1st stage” and “2nd stage” terminology are not synonymous with the
traditional phase 1 and phase 2 terminology. Rather, the seamless framework means
that phase 1 and phase 2 occur throughout both stages. As we will show, the staging
protects patients by allowing to stop for futility.
The data to be collected for each subject are dose level, occurrence of dose limiting
toxicity (DLT), and indicator of response. The true MTD is the dose level with true
probability of DLT closest to some pre-specified threshold, usually between 0.25 and
0.35. The objective of seamless oncology trials is typically to establish that the true
response probability at the true MTD exceeds some minimal efficacy boundary.
Well-designed seamless trials should guard against two distinct errors: the MTD may be
incorrectly estimated and/or the estimated response rate may be inefficient or biased.
Either error decreases the probability of correctly estimating the efficacy at the true MTD,
and moreover, the consequences of either error may be different.
Remark 2 Because our goal is simplicity, the modules currently implemented assume
that the probabilities of DLT and response for each dose are mutually independent.
However, additional modules that relax this assumption could be implemented.

2.2

Module 1: Dose Assignments for 1st Stage

An initial cohort of n1 subjects is enrolled and followed for DLT and/or response, which
are assumed to be binary. Subjects may be adaptively assigned to one of several dose
levels based upon the observed dose-toxicity relationship in the previous subjects, or all
subjects in this module may be enrolled to a fixed dose level, and the sole primary
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Stage 1
Module 1

Stage 2
Module 2

Module 3

Module 4

crm
bayes
$n
$prob_threshold
$skeleton
$prob_means
$starting_dose
$prior_n_per
$beta_scale
$dose_cohort_size
$dose_cohort_size_first_only
$earliest_stop

crm
bayes
$n
$prob_threshold
$skeleton†
$prob_means
$beta_scale†
$prior_n_per
$dose_cohort_size
$include_stage1_data
$dose_cohort_size_first_only
$earliest_stop

3pl3
$starting_dose

bayes_isoreg
$prob_threshold
$alpha_scale

3pl3

empiric
$n
$starting_dose
$rule
$first_patient_look
$thresh_decrease

inverted_score
empiric
$ci_level_onesided$n
$rule
$first_patient_look
$thresh_decrease

inverted_score
$ci_level_onesided
$include_stage1_data

fixed
$n
$starting_dose

min_num_resp
$number

fixed
$n
$include_stage1_data

min_num_resp
$number

min_pct_resp
$percent

continume_crm‡
$n

min_pct_resp
$percent
$include_stage1_data

none

none

none

bayes_isoreg
$prob_threshold
$alpha_scale
$include_stage1_data

Table 1: Module options currently implemented in the seamless design trial simulator.
The option names are in bold, and the names immediately below each option, which
follow the ‘$’ symbol, give the inputs required for that option.
† these arguments are optional if module 1 is crm. If this is the case and these arguments are not
provided, the module 1 options will be used.
‡ this option can only be selected if module 1 is crm because this indicates a simple continuation of that
crm

endpoint is response. Depending on the aims of the trial, a dose-modifying or fixed-dose
module is possible.
We recommend the model-based CRM for module 1 [6, 10] (crm, Table 1). In this
design, the first subject is assigned to a pre-specified starting dose. A statistical model is
fit to estimate the DLT probabilities for each dose based upon the first subject’s data; this
model is usually fit using Bayesian methods to account for sparsity in the data. The MTD
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is estimated after the first subject, and the next subject is assigned to the new estimated
MTD. With each subsequent enrollment, the MTD is re-estimated using all previous
subjects’ data.
There are usually safety constraints accompanying the CRM to avoid unsafe
escalation [41]. These include never escalating more than one dose level per subject,
never escalating before at least one subject has completed a full DLT window at the
current dose, and stopping the trial for toxicity if no dose falls below the toxicity
threshold.
We have implemented other options for module 1 in our simulator, including the
3+3 algorithm (3pl3); a de-escalation scheme that lowers the assigned dose whenever
some percentage of subjects experience a DLT at the current dose level (empiric); and
a fixed dose-assignment scheme (fixed). None of these alternatives explicitly estimate
the MTD but instead simply assign dose levels according to a rule-based algorithm.

2.3

1st Stage Futility Analysis (Module 2)

Due to the longer timeframe typically required to observe response, it may be infeasible
to re-evaluate the dose-response curve after each subject as is done with the
dose-toxicity curve. Rather, it is common to assess efficacy at a few discrete time points
during the trial. Module 2 demarcates the first such time point in our framework. Module
1 ends after dose assignments have been made for n1 subjects, and module 2 occurs
when response has been measured for them.
Module 2 is a gatekeeper: if the probability of finding evidence for efficacy at the
end of the trial, given the data thus far, is low, then the trial should stop. If module 1
assigned all n1 subjects to the same dose level, then module 2 can be as simple as
requiring a minimum number of responders in order to proceed (min_num_resp). In the
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absence of any subsequent modules, this would be the single-stage design of A’hern
[42]. If dose assignments vary from subject to subject, such that the actual number of
subjects at the estimated MTD is likely to be less than n1 , then it would make more
sense to require a minimum proportion of responders in order to proceed
(min_pct_resp). Even this may be insufficient, as simply requiring a proportion does not
take into account uncertainty in observed response rates; this can be achieved by
calculating a confidence interval for the probability of response at the estimated MTD,
e.g. based on the inverted score test [inverted_score 43].
We also implement a Bayesian version (bayes, Table 1), which, assuming that the
efficacy at the estimated MTD is a random variable, calculates the posterior probability
that efficacy at the MTD exceeds some minimal response rate. The trial continues only if
this posterior probability exceeds some prespecified value. It is common to assume that
the distribution of the random variable is Beta, with hyperparameters a1 > 0 and a2 > 0,
which can be linked to prior beliefs about the mean historical response probability,
a1 /(a1 + a2 ), and the historical effective sample size, a1 + a2 . This is akin to the prior
elicitation approach of Mayo and Gajewski [44].
One limitation facing all of the above approaches when the dose-assignment
scheme in module 1 is adaptive is that the number of subjects at the estimated MTD can
be highly variable. As an extreme example, suppose that, after the n1 th subject, the
dose-assignment mechanism updates the estimated MTD to a never-before-tried dose
level. If no dose-response model is in place, and assuming a Bayesian perspective, then
the distribution of the MTD’s efficacy will be entirely prior-driven. This is undesirable
behavior if there is evidence that the response rate at the dose level just above the
estimated MTD is itself quite low, the knowledge of which would actually suggest
stopping for futility. A parametric dose-response model, e.g. logistic regression or a
CRM-type model, could help overcome this limitation. Alternatively, one could impose a
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weaker assumption that the true probability of response is simply non-decreasing
between dose levels. To this end, our recommendation for module 2 is a novel Bayesian
variant of isotonic regression that we have developed (bayes_isoreg, Table 1), which we
briefly describe in Supplement 1. In standard isotonic regression, observing a large
response rate at a lower dose level would be taken as evidence that the response rates
at high dose levels are also large and, conversely, observing a small response rate at a
higher dose level is taken as evidence that the response rate at low dose levels is also
small [45]. Standard isotonic regression may be inadequate under sparse data
scenarios, and our Bayesian variant addresses this limitation.

2.4

Dose Assignments for 2nd Stage (Module 3)

Seamless trials often enroll a second cohort of n2 subjects, either using an adaptive
dose-assignment scheme or at a fixed dose level, sometimes called a ‘dose expansion
cohort’ [DEC, 30]. Module 3, which delineates this next set of dose assignments, can be
any of the options used in module 1, but the starting dose is now the estimated MTD
from module 1. An expansion cohort starting at the estimated MTD with or without a
simple de-escalation rule would be simulated using empiric or fixed, respectively (Table
1).
Because the estimated MTD is subject to uncertainty, we recommend that module
3 continue adaptive dose assignments and re-estimation of the MTD [31, 32]. Under this
recommendation, an entirely new CRM could be initiated, starting at the previously
estimated MTD (crm), or the CRM from module 1 could resume at the exact state it
ended at in module 1 (continue_crm). Alternatively, a new 3+3 starting at the estimated
MTD could be selected (3pl3). Finally, module 3 can be skipped altogether if no second
stage is required (none).

11

2.5

Dose Recommendation (Module 4)

A final efficacy analysis is conducted at the end of the trial, either using all enrolled
subjects’ data or data from just the second stage. The design choices for module 4 are
the same as for module 2, and all of the same options exist (bayes, bayes_isoreg,
inverted_score, min_num_resp, and min_pct_resp).

3
3.1

Results
Trial Simulator: Description

We present a numerical study of our seamless trial simulator to demonstrate how it can
be used to compare the performance of heterogenous seamless trial designs. Code and
instructions for recreating the simulation study, which makes use of our seamlesssim R
package, are available in a separate GitHub repository [46], and the instructions are
reprinted in Supplement 2. Ten data-generating scenarios were considered; the true
dose-toxicity and dose-response curves are given with the results in Figures 2–4 and
Figure S2 in Supplement 1. For all scenarios, the true MTD was the dose level with true
probability of DLT closest to 0.25 but not exceeding 0.30, and an ‘acceptable’ dose level
was defined as any dose level with true probability of DLT not exceeding 0.30 and true
probability of response at least 0.20. Based on this definition, two scenarios (numbers 7
and 9) had no acceptable dose levels, and three scenarios (1, 3, and 10) had two
acceptable dose levels. The remaining five had exactly one acceptable dose level.
We compared six designs comprising combinations of modules: two choices of
dose-assignment mechanism each combined with three different efficacy analyses. All
designs are described in Table 2. The first dose-assignment mechanism is a ‘3+3’
algorithm (module1 = 3pl3), which will have a maximum sample size of 6 patients per
12

Design name

module 1

module 2

module 3

module 4

max n1 + n2

3pl3:Bayes:DEC:Bayes
3pl3:none:DEC:Bayes
3pl3:none:DEC:BIsoReg
CRM:Bayes:CRM:Bayes
CRM:none:CRM:Bayes
CRM:none:CRM:BIsoReg

3pl3
3pl3
3pl3
crm
crm
crm

bayes
none
none
bayes
none
none

empiric
empiric
empiric
crm
continue_crm
continue_crm

bayes
bayes
bayes_isoreg
bayes
bayes
bayes_isoreg

65
65
65
60
60
60

Table 2: Choice of modules for six designs considered. The upper three designs will
enroll up to n1 = 30 patients (cohorts of six for each of five dose levels) in module 1 and
n2 = 35 in module 3; the lower three designs will enroll up to n1 + n2 = 60 subjects across
both modules.
dose level, or n1 = 30 patients, followed by a fixed DEC of size n2 = 35 (module3 =
empiric); the DEC enrolls subjects at the estimated MTD from the ‘3+3’ algorithm and
only de-escalates if the observed DLT rate after the first 10 patients in the cohort
exceeds 33%. The second dose-assignment mechanism is a CRM (module1 = module3
= crm) with n1 = 25 and n2 = 35 subjects in the first and third modules, respectively.
We evaluated three sets of efficacy analyses. The first utilized a Bayesian futility
analysis (module2 = bayes) and a final Bayesian analysis (module4 = bayes); the second
conducted only a final Bayesian analysis (module4 = bayes); and the third implemented
our Bayesian isotonic regression at the end (module4 = bayes_isoreg). To compare
between all six designs, the module 2 and module 4 efficacy parameters were set so that
the probability of recommending the MTD in scenario 9 was about 0.10. This
corresponds to a type I error (false positive) rate of 0.10, since the MTD is not acceptable
in this scenario. For each of the 60 combinations of six designs and ten scenarios, we
ran 2000 simulated trials.

3.2

Trial Simulator: Results

Figures 2 and 3 display the simulation-based probability of recommending any dose and
whether or not that recommendation was a good one. Each figure gives a set of three
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designs, grouped by choice of dose-assignment mechanism. When at least one dose
level is acceptable, as in scenarios 1–6, 8, and 10, there are three possible outcomes to
the trial – no recommendation, recommendation of an unacceptable dose, or
recommendation of an acceptable dose – and when no dose levels are acceptable, as in
scenarios 7 and 9, there are two possible outcomes – no recommendation or
recommendation of an unacceptable dose.
From Figure 2, which contains the 3+3-type designs, whether or not there is an
interim futility analysis in module 2, i.e. comparing 3pl3:Bayes:DEC:Bayes to
3pl3:none:DEC:Bayes, has relatively little impact on the probability of making a correct
dose recommendation. This is not surprising, given that the DEC in module 3 is unlikely
to change the estimated MTD unless extreme toxicity is observed, making this
comparison analogous to that of a two-stage phase II design against a one-stage phase
II design. In contrast, the use of a Bayesian isotonic regression in module 4 in place of
independent beta priors on each dose level, i.e. comparing 3pl3:none:DEC:Bayes to
3pl3:none:DEC:IsoReg, generally increases the overall probability of recommending a
dose level. That is, the ‘No Rec (correct)’ and ‘No Rec (wrong)’ proportions are generally
larger for 3pl3:none:DEC:Bayes, and the ‘Rec (unaccept)’ and ‘Rec (accept)’ proportions
are generally larger for 3pl3:none:DEC:BIsoReg. These differences range from 1–4%
across all ten scenarios. This is also an expected finding, since sharing information
between dose levels allows the isotonic regression to more easily recommend dose
levels.
Figure 3 gives the same sets of results for the CRM-type designs, all of which have
the same maximum possible sample size of n1 + n2 = 60 subjects. As expected, the
CRM-type designs select an acceptable dose with higher probability than the 3+3-type
designs. Moreover, in contrast to Figure 2, the interim efficacy analysis has a greater
effect on the final outcome of the trial, as seen from comparing CRM:Bayes:CRM:Bayes
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to CRM:none:CRM:Bayes. This is likely because of the final 35 patients of the trial, who
are only enrolled to CRM:Bayes:CRM:Bayes if the module 2 efficacy analysis is passed.
Comparing CRM:none:CRM:Bayes to CRM:none:CRM:BIsoReg, the isotonic regression
generally increases the recommendation probability.
Figure 4 gives the distribution of dose assignments at subjects 10, 30, and 50 for
the three CRM-type-designs. Analogous results for the 3+3-type-designs are given in
Figure S2 of Supplement 1. For the CRM designs, as the trial proceeds, subjects are
assigned to the preferred dose level in increasing proportions. Although the 3+3 designs
generally assign the 10th subject to the preferred dose with high probability, their
performance degrades as the trial proceeds, meaning that the 30th and 50th subjects
are often assigned to the preferred dose level with small probabilities. This is an
expected result given the known deficiencies of the 3+3, but the inclusion of the interim
efficacy analysis would make it difficult to quantify these probabilities in the absence of
this simulator. Comparing Figure 4 to Figure S2, CRM:none:CRM:BIsoReg is uniformly
preferred to 3pl3:Bayes:DEC:Bayes except for scenarios 7 and 9, in which no dose levels
are acceptable in truth. Based on this, we would conclude that CRM:none:CRM:BIsoReg
would be improved with a choice of module 2 = bayes_isoreg, if we were actually
proposing the design for a clinical protocol.

4

Conclusion

This paper characterizes seamless oncology trial design in a modular framework, which
confers several advantages. It formalizes each decision needed for a seamless-type trial,
including a provision for interim futility analyses. It puts forward a concrete definition of a
‘seamless trial’, namely any logically coherent set of modules. Because this modular
framework is implemented in seamlesssim[11], a freely available R package and an
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Figure 2: Simulation-based probability of outcomes (based on 2000 simulations) for three designs (out of
six total) across ten scenarios, separated into whether or not any dose level was recommended and whether
or not that outcome was acceptable or not. The right-hand column gives the true generating toxicity and
efficacy curves. Each row corresponds to a different scenario, and consecutive pairs of scenarios (1&2,
3&4, etc.) are linked in that they share a common dose-toxicity curve but differ in the dose-response curve.
Figure 3 gives the same results for three different designs.
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Figure 3: Simulation-based probability of outcomes (based on 2000 simulations) for three designs (out of
six total) across ten scenarios, separated into whether or not any dose level was recommended and whether
or not that outcome was acceptable or not. The right-hand column gives the true generating toxicity and
efficacy curves. Each row corresponds to a different scenario, and consecutive pairs of scenarios (1&2,
3&4, etc.) are linked in that they share a common dose-toxicity curve but differ in the dose-response curve.
Figure 2 gives the same results for three different designs.
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Figure 4:

Distribution of dose assignments at subjects 10, 30, and 50 (based on 2000 simulations)
for three CRM-type designs (out of six total) across ten scenarios. The right-hand column gives the true
generating toxicity and efficacy curves. Each row corresponds to a different scenario, and consecutive pairs
of scenarios (1&2, 3&4, etc.) are linked in that they share a common dose-toxicity curve but differ in the
dose-response curve. The proportion(s) corresponding to the preferred dose level are bordered by a solid
box. If a trial has stopped for futility or safety, the patient was treated as having been assigned to dose level
18for the three 3+3-type designs.
‘0’. Figure S2 in Supplement 1 gives the same results

accompanying vignette that together form the main contribution of this paper, it is
possible to quantify design decisions’ impact on operating characteristics. By providing
the trial simulator, we have made it simpler for clinical trialists to quantify seamless
design decisions’ impact on operating characteristics. Even very heterogeneous designs
can be compared using our simulator, which reports the same operating characteristics
regardless of the module configuration. These advantages address three key challenges
to the statistical design of seamless trials outlined in Hobbs, et al. [33]: lack of formal
design for DECs, imprecise operating characteristics, and difficulties in implementing
interim safety and futility analyses. Future extensions could use the time-to-event-CRM
[47] in Modules 1 and 3 as a means of handling late-onset toxicities. Another important
direction would be to extend Modules 2 and 4 to estimate an optimal biological dose or
minimum efficacious dose.
Although our primary goal was not to recommend a particular configuration of
modules, our findings reiterate the importance of keeping the dose assignment
mechanism open for the full duration of the trial and efficiently sharing information across
dose levels and stages. With regard to this second point, an isotonic regression model
for estimating dose-response curves, such as bayes_isoreg, is sensible. This approach
could also be adapted as an option for module 1 or module 3, to estimate the
dose-toxicity curve.
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